There are currently 2876 clinical trials in Houston, Texas looking for participants to engage in research studies. Trials are conducted at various facilities, including M D Anderson Cancer Center, University of Texas MD Anderson Cancer Center, Baylor College of Medicine and The University of Texas - MD Anderson Cancer Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Abbott Ventricular Tachycardia PAS
NCT05839873
Recruiting
This post-approval study (PAS) is designed to provide continued clinical evidence to confirm the long-term safety and effectiveness of the FlexAbilityTM Ablation Catheter, Sensor EnabledTM (FlexAbility SE) for the treatment of ventricular tachycardia in a post-market environment. This is a prospective, single arm, open-label, multi-center, observational study.
Gender:
ALL
Ages:
7 years and above
Trial Updated:
07/08/2025
Locations: Memorial Hermann Hospital, Houston, Texas
Conditions: Ventricular Tachycardia
Register for Updates
Maturation of Arteriovenous Fistula With Automated Sonography Assessments Trial
NCT06190717
Recruiting
This is a prospective, multi-center, two-arm, randomized trial to quantify the performance of the EchoMark®/EchoSure® System for AVF diagnostic ultrasound when used under a protocol of biweekly use for assessing fistula maturation and reducing time to Clinical Maturation.
Gender:
ALL
Ages:
Between 18 years and 84 years
Trial Updated:
07/08/2025
Locations: Aqua Research Institute Llc, Houston, Texas
Conditions: Diabetes, End Stage Renal Disease
Register for Updates
A Study of Pitolisant in Patients With Prader-Willi Syndrome
NCT06366464
Recruiting
This is a Phase 3, randomized, double-blind, placebo-controlled, multicenter, global clinical study to assess the efficacy and safety of pitolisant in patients living with Prader-Willi syndrome. The primary objective of this study is to evaluate the efficacy of pitolisant in treating excessive daytime sleepiness (EDS) in patients ≥6 years of age with Prader-Willi syndrome. Secondary objectives include assessing the impact of pitolisant on: Irritable and disruptive behaviors Hyperphagia Other... Read More
Gender:
ALL
Ages:
6 years and above
Trial Updated:
07/08/2025
Locations: Texas Children's Hospital, Houston, Texas
Conditions: Prader-Willi Syndrome
Register for Updates
Comprehensive Yoga Therapy Based Lifestyle Prehabilitation Program for Women With Ovarian Cancer
NCT06545604
Recruiting
To provide a comprehensive yoga therapy (CYT) program to patients with ovarian, fallopian tube, or primary peritoneal cancer who are scheduled to receive chemotherapy and then undergo surgery. Researchers want to learn about the effects of the program on patients' quality of life and other outcomes described below.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: Ovarian Cancer
Register for Updates
A Study to Investigate the Safety and Efficacy of TMP-301 Compared to Placebo in Adult Patients With Alcohol Use Disorder
NCT06648655
Recruiting
TMP-301 has been shown in preclinical models to reduce consumption of alcohol and other addictive substances. It has been tested in healthy subjects and has been found to be safe and tolerated at doses predicted to be efficacious in alcohol use disorder. This study is being conducted to evaluate the safety, tolerability and efficacy of TMP-301 in patients with alcohol use disorder.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
07/08/2025
Locations: Baylor College of Medicine, Houston, Texas
Conditions: Alcohol Use Disorder (AUD)
Register for Updates
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394
Recruiting
This (DEEp SEA Study) is a double-blind, randomized, placebo-controlled, multicenter study to investigate the efficacy, safety, and tolerability of LP352 in the treatment of seizures in children and adults with DS. The study consists of 3 main phases: Screening, Titration period, and Maintenance period, followed by a Taper period and Follow-Up. Participants will be randomized to LP352 or placebo. The total duration of the study will be approximately 24 months.
Gender:
ALL
Ages:
Between 2 years and 65 years
Trial Updated:
07/08/2025
Locations: Site Number - USA25, Houston, Texas
Conditions: Dravet Syndrome
Register for Updates
Bone Stimulator for Spondylolysis
NCT06666608
Recruiting
This prospective study aims to investigate the effectiveness of bone stimulator therapy as adjunct treatment of spondylolysis in athletic populations. By evaluating its impact on pain reduction, functional improvement, osseous bony union and return-to-sport time, the investigators seek to provide valuable insights into the role of bone stimulation therapy as a potential treatment modality for this challenging condition.
Gender:
ALL
Ages:
Between 16 years and 40 years
Trial Updated:
07/08/2025
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Spondylolysis, Symptomatic Spondylolysis, Athletes
Register for Updates
Anterior Cruciate Ligament (ACL) Reconstruction With Autologous Fat Pad Derived Mesenchymal Stem Cells
NCT06798623
Recruiting
This study is designed as a prospective, open label, single arm pilot clinical study that will establish the safety and efficacy of a single injection of mesenchymal stromal cells in patients. Each subject will receive one intra-articular injection of autologous mesenchymal stromal cells derived from infrapatellar fat pad (FP-MSC) tissue samples collected from the subject during anterior cruciate ligament (ACL) reconstruction surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: Houston Methodist Hospital, Houston, Texas
Conditions: Anterior Cruciate Ligament Reconstruction
Register for Updates
A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors
NCT06859762
Recruiting
A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Advanced Solid Tumor
Register for Updates
A Study of HS-20110 in Participants With Advanced Solid Tumors
NCT06892379
Recruiting
This is an open-label, multicenter study to evaluate the safety and tolerability of HS-20110 in participants with advanced solid malignant tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: The University of Texas MD Anderson Cancer Center, Houston, Texas
Conditions: Solid Tumors
Register for Updates
A Study of CBX-250 in Participants With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
NCT06994676
Recruiting
Study CBX-250-001 is a Phase 1, open-label, dose-escalation study of CBX-250 in participants with relapsed/refractory AML, HR-MDS and CMML. Participants aged ≥ 12 years are planned to be enrolled. CBX-250 will initially be investigated on a fixed step-up dosing schedule. CBX-250 will be administered subcutaneously in 28-day cycles, with the first study drug dose administered on Cycle 1, Day 1. Cycle 1 will consist of a priming phase over 7 days, and a target phase over 28 days. Participants will... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
07/08/2025
Locations: MD Anderson Cancer Center, Houston, Texas
Conditions: High-risk Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (CMML), AML - Acute Myeloid Leukemia
Register for Updates
A Study to Investigate the Safety and Efficacy of KQB168 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies
NCT06994806
Recruiting
The goal of this clinical trial is to learn if KQB168 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB168. The main questions it aims to answer are: * What is the safe dose of KQB168 by itself or in combination with pembrolizumab? * Does KQB168 alone or in combination with pembrolizumab decrease the size of the tumor? * What happens to KQB168 in the body? Participants will: * Take KQB168 daily, alone or in combination with pembrolizumab * Visit... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/08/2025
Locations: NEXT Huston, Houston, Texas
Conditions: Solid Tumor Malignancies
Register for Updates